Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamsulosin and hydrochlorothiazide for stone excretion after ESWL
IRCT20200704047998N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tamsulosin and hydrochlorothiazide in ureterolithiasis and nephrolithiasis (4 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Effect of the drug on stone excretion. Started May 2019; status: completed.
02
Drugs
tamsulosinhydrochlorothiazide
03
Conditions
ureterolithiasisnephrolithiasis
Beyond the preview
Go deeper on IRCT20200704047998N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200704047998N1.